3703
document
Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis . Patients with acute exacerbations of chronic bronchitis were treated with cefdinir 300 mg bd for 5 days or cefprozil 500 mg bd for 10 days in a prospective , randomized , double-blind , multicentre study . Of the 548 patients enrolled , 281 ( 51 % ) were evaluable . The clinical cure rates at the test-of-cure visit were 80 % ( 114/142 ) and 72 % ( 100/139 ) for the evaluable patients treated with cefdinir and cefprozil , respectively . Respiratory tract pathogens were isolated from 409 ( 75 % ) of 548 admission sputum specimens , with the predominant pathogens being Haemophilus parainfluenzae , Haemophilus influenzae , Staphylococcus aureus and Moraxella catarrhalis . The microbiological eradication rates at the test-of-cure visit were 81 % ( 157 of 193 pathogens ) and 84 % ( 166 of 198 pathogens ) for the evaluable patients treated with cefdinir and cefprozil , respectively . Adverse event rates while on treatment were equivalent between the two treatment groups . The incidence of diarrhoea during therapy was higher for patients treated with cefdinir ( 17 % ) than for patients treated with cefprozil ( 6 % ) ( P < 0.01 ) , but most cases were mild and did not lead to discontinuation of treatment . These results indicate that a 5 day regimen of cefdinir is as effective and safe in the treatment of patients with acute exacerbations of chronic bronchitis as a 10 day regimen of cefprozil .
3704
Intervention_Pharmacological
cefdinir
3705
Intervention_Pharmacological
cefprozil
3706
Intervention_Pharmacological
cefdinir
3707
Intervention_Pharmacological
cefprozil
3708
Intervention_Pharmacological
cefdinir
3709
Intervention_Pharmacological
cefprozil
3710
Intervention_Pharmacological
cefdinir
3711
Intervention_Pharmacological
cefprozil
3712
Intervention_Pharmacological
cefdinir
3713
Intervention_Pharmacological
cefprozil
3714
Intervention_Pharmacological
cefdinir
3715
Intervention_Pharmacological
cefprozil
3716
Outcome_Physical
acute exacerbations of chronic bronchitis .
3717
Outcome_Other
clinical cure rates
3718
Outcome_Physical
Respiratory tract pathogens
3719
Outcome_Physical
microbiological eradication rates
3720
Outcome_Adverse-effects
Adverse event rates
3721
Outcome_Adverse-effects
incidence of diarrhoea
3722
Outcome_Other
effective and safe
3723
Outcome_Physical
acute exacerbations of chronic bronchitis
3724
Participant_Condition
acute exacerbations of chronic bronchitis
3725
Participant_Sample-size
548
3726
Participant_Sample-size
281
3727
Participant_Condition
cefdinir and cefprozil
3728
Participant_Condition
cefdinir
3729
Participant_Condition
acute exacerbations of chronic bronchitis